While clinical factors such as prostate-specific antigen (PSA) values, T-category, and Gleason scores have traditionally been used to risk-stratify prostate cancer patients, their accuracy is low (25%–40%) to predict important end points such as progression or metastases after radiation and ADT [4,5]. The gene discussed is KLK3; the disease is prostate carcinoma.